Trials / Completed
CompletedNCT01419717
Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 129 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial will facilitate access to denosumab for adults with advanced cancer who have participated in a denosumab phase 3 study until denosumab is approved and available for sale.
Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer
- Bone Metastases in Subjects With Advanced Breast Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Denosumab | Administered by subcutaneous injection every 4 weeks (Q4W) |
Timeline
- Start date
- 2011-11-22
- Primary completion
- 2018-08-10
- Completion
- 2018-08-10
- First posted
- 2011-08-18
- Last updated
- 2019-09-24
- Results posted
- 2019-09-09
Locations
64 sites across 19 countries: Argentina, Austria, Belgium, Brazil, Czechia, France, Hungary, Israel, Italy, Japan, Latvia, Lithuania, Panama, Peru, Poland, Russia, South Africa, Spain, Ukraine
Source: ClinicalTrials.gov record NCT01419717. Inclusion in this directory is not an endorsement.